Previous Close | 2.5300 |
Open | 2.5500 |
Bid | 2.4000 x 800 |
Ask | 2.6200 x 1100 |
Day's Range | 2.3350 - 2.6986 |
52 Week Range | 1.3500 - 4.4000 |
Volume | |
Avg. Volume | 70,209 |
Market Cap | 127.397M |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7570 |
Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for AXLA
CAMBRIDGE, Mass., August 12, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.
Absci, Axcella Health, Freeline Therapeutics Holdings, DICE Therapeutics and Pliant Therapeutics are part of Zacks top Analyst Blog.
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.